MMP2 and prostate carcinoma: A pre-metastatic conditioning study using exosomes derived from hypoxic prostate cancer cells revealed the highest MMP (MMP9 and MMP2) activity in prostate cancer target metastatic organs, such as the liver, kidney, and spleen [56].